日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Cerebrospinal fluid CXCL10 is associated with the presence of low level CSF HIV during suppressive antiretroviral therapy.

在接受抑制性抗逆转录病毒治疗期间,脑脊液 CXCL10 与脑脊液中低水平 HIV 的存在有关

Anderson Albert M, Kundu Suprateek, Tang Bin, Vaida Florin, Okwuegbuna Oluwakemi, McClernon Daniel, Cherner Mariana, Deutsch Reena, Cookson Debra, Crescini Melanie, Grant Igor, Zetterberg Henrik, Blennow Kaj, Gisslen Magnus, Ellis Ronald J, Letendre Scott L

Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy

抗逆转录病毒治疗期间脑脊液中持续存在HIV-1 RNA的流行率及其相关因素

Anderson, Albert M; Muñoz-Moreno, Jose A; McClernon, Daniel R; Ellis, Ronald J; Cookson, Debra; Clifford, David B; Collier, Ann C; Gelman, Benjamin B; Marra, Christina M; McArthur, Justin C; McCutchan, J Allen; Morgello, Susan; Sacktor, Ned; Simpson, David M; Franklin, Donald R; Heaton, Robert K; Grant, Igor; Letendre, Scott L

Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study

洛匹那韦/利托那韦单药长期治疗对脑脊液病毒学疗效和神经认知状态的影响:一项探索性研究

Santos, José R; Muñoz-Moreno, José A; Moltó, José; Prats, Anna; Curran, Adrià; Domingo, Pere; Llibre, Josep M; McClernon, Daniel R; Bravo, Isabel; Canet, Jaume; Watson, Victoria; Back, David; Clotet, Bonaventura

A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)

一项随机对照试验,比较了 HIV 感染患者在 48 周内接受阿巴卡韦/拉米夫定/齐多夫定每日两次初始抗逆转录病毒疗法与阿扎那韦每日一次联合拉米夫定/齐多夫定每日两次初始抗逆转录病毒疗法的效果(ESS100327,ACTION 研究)。

Kumar, Princy N; Salvato, Patricia; LaMarca, Anthony; DeJesus, Edwin; Patel, Parul; McClernon, Daniel; Florance, Allison; Shaefer, Mark S